Greater Midwest Financial Group LLC Has $2.21 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Greater Midwest Financial Group LLC grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 23.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,108 shares of the biopharmaceutical company’s stock after acquiring an additional 588 shares during the period. Regeneron Pharmaceuticals comprises about 1.4% of Greater Midwest Financial Group LLC’s portfolio, making the stock its 19th largest holding. Greater Midwest Financial Group LLC’s holdings in Regeneron Pharmaceuticals were worth $2,214,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of REGN. Rakuten Securities Inc. boosted its position in Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 19 shares during the period. FSA Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at about $26,000. Fairfield Financial Advisors LTD bought a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at about $37,000. Truvestments Capital LLC acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth approximately $39,000. Finally, Valley Wealth Managers Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth approximately $49,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $694.64 on Friday. The firm’s fifty day moving average price is $730.57 and its two-hundred day moving average price is $942.10. The stock has a market cap of $76.33 billion, a PE ratio of 17.19, a PEG ratio of 1.59 and a beta of 0.10. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $666.25 and a fifty-two week high of $1,211.20.

Wall Street Analysts Forecast Growth

REGN has been the subject of several research reports. Royal Bank of Canada dropped their price target on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Canaccord Genuity Group began coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target on the stock. Piper Sandler dropped their price objective on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Oppenheimer decreased their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Finally, Truist Financial dropped their price target on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,015.38.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.